Table 1. Baseline patients’ characteristics (N=33).
| Characteristics | Number of patients N (%) |
|---|---|
| Age (years) | |
| Median (range) | 58 (36–75) |
| Menopause at study entry | 30 (90.9) |
| WHO performance status | |
| 0 | 15 (46.9) |
| 1 | 17 (53.1) |
| Missing | 1 (3.0) |
| Hormonal status | |
| ER-positive and/or PgR-positive | 13 (39.4) |
| ER-negative and PgR-negative | 18 (54.5) |
| Missing | 2 (6.1) |
| HER2 status | |
| IHC 3+ | 28 (84.8) |
| IHC 2+ and FISH positive | 5 (15.2) |
| Metastatic status | |
| Number of sites: median (range) | 2 (1; 7) |
| Liver/lung/both | 18/13/7 |
| Bone/bone only | 14/1 |
| Brain/brain only | 5/1 |
| Previous treatments | |
| Radiotherapy | 28 (84.8) |
| Hormonotherapy | 15 (45.5) |
| Trastuzumab 1 line | 21 (63.6) |
| Trastuzumab 2 lines | 12 (36.4)a |
| Median number of lines of chemotherapy (range) | 2 (1; 5) |
Abbreviations: ER=estrogen receptors; FISH=fluorescence in situ hybridisation; IHC=immunohistochemistry; PgR=progesterone receptors.
a
Two patients had received three lines of trastuzumab before enrollment.